Behavioral Pharmacological Examination of a Novel Buprenorphine Induction Method Among Individuals Who Use Fentanyl (NBIM)

January 15, 2025 updated by: Johns Hopkins University
The opioid overdose epidemic has persisted for several decades and is now further complicated by the permeation of fentanyl into the illicit opioid supply. While the effectiveness of medications to treat opioid use disorder (MOUD) have been well documented in the literature, the addition of fentanyl to the drug supply has complicated the initiation of MOUD, especially buprenorphine. Naloxone, an opioid antagonist, is currently utilized to reverse opioid overdose by displacing less-competitive ligands which bind at the mu-opioid receptor. Because induction to buprenorphine in the age of fentanyl is uncomfortable and can take several days to stabilize a patient on a therapeutic dose, the use of naloxone prior to buprenorphine can aid in a safe and rapid transition to buprenorphine treatment, without the effect of unintended prolonged precipitated withdrawal which can occur following the displacement of fentanyl by buprenorphine on the mu-opioid receptor. Therefore, this project will assess feasibility and acceptability of naloxone-facilitated buprenorphine initiation using a single-ascending dose design. The investigators will examine whether a single dose of buprenorphine is tolerated following administration of naloxone among a small group of individuals. If the dose is tolerated, the investigators will administer a larger dose among another small group of individuals. The investigators will examine the tolerability of up to 4 doses of buprenorphine following naloxone. This buprenorphine induction method has been characterized in case studies but it has not been evaluated in an empirical, systematic way in a controlled setting. This study will take place within an residential facility at Johns Hopkins Bayview Medical Campus, and will have immediate, real-world applicability in establishing a rapid, safe, and effective option to transition people with chronic fentanyl use to buprenorphine treatment.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

Emergent data suggest that individuals with fentanyl use experience prolonged, uncomfortable buprenorphine inductions that can commonly result in instances of unintended precipitated withdrawal. Buprenorphine induction in the fentanyl era can take multiple days, which is time intensive and increases the risk for treatment attrition. Novel methods that transition patients quickly and safely from fentanyl to buprenorphine are needed.

The proposed project will evaluate the feasibility and acceptability of naloxone-facilitated buprenorphine inductions among individuals with recent fentanyl exposure. The project consists of a single ascending dose study to assess feasibility and acceptability of naloxone-facilitated buprenorphine inductions.

Participants with opioid use disorder with fentanyl exposure who are not receiving medications for opioid use disorder will complete a brief phone or online prescreen to assess initial eligibility. Potentially eligible participants will be contacted by research staff to complete an in-person screen and informed consent form with a staff member and discuss the study before providing voluntary informed consent to participate. The screen contains structured demographics, substance use, and overall health questions from standard assessments and from internally developed survey items in order to determine study specific eligibility.

Eligible participants will enroll in a 2-3 day residential stay at a clinical research unit at Johns Hopkins University Bayview Campus. Throughout the residential stay, participants will complete frequent measures of withdrawal, craving, and anxiety. Participants may be maintained on hydromorphone for the first 24 hours depending on the timing of the participants admission. In a single-ascending dose design, the investigators will incrementally assess the tolerability of 4, 8, 16, and 24 mg of buprenorphine following naloxone administration (Narcan, 4 mg) among 3 participants per dose condition (e.g., 3 participants will receive 4 mg buprenorphine following naloxone administration then 3 new participants will receive 8 mg buprenorphine following naloxone administration, etc.). Immediately before naloxone administration and in 15-minute increments for 2 hours following naloxone administration, participants will be assessed for opioid withdrawal. These assessments will characterize the naloxone-induced opioid withdrawal and any evidence for buprenorphine-precipitated withdrawal. Following administration of buprenorphine, if there is no evidence of buprenorphine precipitated withdrawal within 45 minutes, the investigators will administer another dose of buprenorphine and will continue to dose the participant until the participant reaches stabilization (between 16mg and 24mg). The participant will stay an additional night for observation and will be discharged on the third day. All participants will be discharged with a short supply of buprenorphine and will be connected to a medical provider for continued buprenorphine prescribing. The Clinical Opiate Withdrawal scale (COWS) and the Subjective Opiate Withdrawal Scale (SOWS) will be assessed at regular intervals, multiple times throughout the stay to monitor withdrawal.

Study Type

Interventional

Enrollment (Estimated)

25

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • United States
    • Maryland
      • Baltimore, Maryland, United States, 21224
        • Recruiting
        • Johns Hopkins School of Medicine
        • Contact:
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • 18 years or older
  • Speak fluent English
  • Medically cleared to take study medication
  • Willing to comply with the study protocol
  • Provides urine sample that tests positive for fentanyl
  • Current moderate to severe opioid use disorder

Exclusion Criteria:

  • Significant cognitive impairment resulting in inability to provide informed consent (e.g., severe dementia or intellectual disability)
  • Unable to read or understand study questions with assistance from the research staff
  • Medical symptoms interfering with their ability to answer study questions
  • Psychiatric symptoms interfering with their ability to answer survey questions
  • Currently enrolled and taking medications for OUD
  • Pregnant or Breastfeeding
  • Taking medication contraindicated with study medication
  • Deemed by the principal investigator or medical team to not be a good fit for the study protocol.
  • Current or history of hypo/hypertension (i.e., no less than 90/60, no greater than 140/90) or adverse cardiovascular event in the past three years (e.g. significant cardiac arrhythmia, myocardiac infarction, endocarditis).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Sequential Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: 4mg buprenorphine
4mg of buprenorphine will be given to a subset of participants immediately after naloxone administration.
Drug: Naloxone Nasal Spray
IN naloxone will be administered to participants, after which a single dose of buprenorphine will be given to participants
Experimental: 8mg buprenorphine
8mg of buprenorphine will be given to a subset of participants immediately after naloxone administration.
Drug: Naloxone Nasal Spray
IN naloxone will be administered to participants, after which a single dose of buprenorphine will be given to participants
Experimental: 16mg buprenorphine
16mg of buprenorphine will be given to a subset of participants immediately after naloxone administration.
Drug: Naloxone Nasal Spray
IN naloxone will be administered to participants, after which a single dose of buprenorphine will be given to participants
Experimental: 24mg buprenorphine
24mg of buprenorphine will be given to a subset of participants immediately after naloxone administration.
Drug: Naloxone Nasal Spray
IN naloxone will be administered to participants, after which a single dose of buprenorphine will be given to participants

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Peak opioid withdrawal as assessed by the Subjective Opiate Withdrawal Scale (SOWS)
Time Frame: After administration of first dose of buprenorphine up to 8 hours
Opioid withdrawal severity will be measured with the Subjective Opiate Withdrawal Scale (SOWS) and will be computed as the peak total SOWS score in the 8 hours after buprenorphine administration. The SOWS consists of 16 opioid withdrawal symptoms that are assessed for severity on a scale from 0-4 ("Not at all" to "Extremely"). Total scores range from 0-64 where a score between 0-10 is considered mild, between 11-20 is considered moderate, and greater than 21 is considered severe.
After administration of first dose of buprenorphine up to 8 hours
Self-report acceptability
Time Frame: 3 days
Acceptability will be measured by an acceptability questionnaire designed by the research team. Items from the questionnaire will be computed as the average acceptability score. Scores range from 0-10, where 0 reflects no acceptability and 10 reflects high acceptability.
3 days
Length of time (hours) for participants to reach 8mg of buprenorphine
Time Frame: After initial buprenorphine dose up to 24 hours
Time between initial buprenorphine dose and time reaching a dose of at least 8mg buprenorphine dosage will be measured to understand how long it takes patients to tolerably receive the minimum maintenance dose of 8mg
After initial buprenorphine dose up to 24 hours

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Johns Hopkins University

Collaborators

Cure Addiction Now

Investigators

  • Principal Investigator: Cecilia Bergeria, PhD, Johns Hopkins School of Medicine

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 9, 2024

Primary Completion (Estimated)

January 1, 2026

Study Completion (Estimated)

January 1, 2026

Study Registration Dates

First Submitted

October 2, 2023

First Submitted That Met QC Criteria

October 13, 2023

First Posted (Actual)

October 18, 2023

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

January 15, 2025

Last Verified

January 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • IRB00392041

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Opioid Use Disorder

Clinical Trials on Naloxone Nasal Spray

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Equatorial Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe